All In Biotech

NDA 217604 · Amneal

Pyridostigmine Bromide

Pyridostigmine Bromide · Oral

Discontinued

Last checked: Nov 20, 2026Latest source record: May 12, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2024

Oct 4, 2024

Approved uses

1

Original approval plus efficacy supplements

Registered trials

45

6 Phase 3, 6 recruiting

FAERS reports

1,907

1,327 serious, 177 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISKS WITH IMPROPER USE OF PYRIDOSTIGMINE BROMIDE After Exposure to Soman, Use Atropine and Pralidoxime Pyridostigmine bromide is for use as a pretreatment for exposure to soman nerve agent. Pyridostigmine bromide alone will not protect against exposure to soman. The efficacy of pyridostigmine bromide is dependent upon the rapid use of atropine and pralidoxime (2-PAM) after soman exposure [see Dosage and Administration (2.1) and Warnings and Precautions (5.1) ]. Always Use Protective Garment(s) Primary protection against exposure to chemical nerve agents is the wearing of protective garments including masks, hoods, and overgarments designed specifically for this use. Individuals must not rely solely upon pretreatment with pyridostigmine bromide and on the antidotes atropine and pralidoxime (2-PAM) to provide complete protection from poisoning by soman nerve agent [see Dosage...

What it is approved for

From the label in effect May 13, 2026.

Pyridostigmine bromide is indicated for pretreatment against the lethal effects of soman nerve agent poisoning in adults. Pyridostigmine bromide is intended for use in conjunction with protective garments, including a mask. At the first sign of nerve agent poisoning, pyridostigmine bromide should be stopped, and atropine and pralidoxime therapy started immediately. The evidence for the effectiveness of pyridostigmine bromide as pretreatment against soman-induced toxicity was derived from animal studies alone [see Clinical Studies (14) ]. FOR MILITARY MEDICAL USE ONLY Pyridostigmine bromide is a cholinesterase inhibitor indicated for pretreatment against the lethal effects of soman nerve agent poisoning in adults. ( 1 ) Pyridostigmine bromide is for use in conjunction with Protective garments, including a gas mask, and Immediate atropine and pralidoxime therapy at the first sign of nerve agent poisoning. ( 1 )

Mechanism: Pyridostigmine is a reversible cholinesterase inhibitor.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 4, 2024 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • PYRIDOSTIGMINE BROMIDE · PYRIDOSTIGMINE BROMIDE 105MG · TABLET, EXTENDED RELEASE, ORAL · Discontinued

Clinical trials

Interventional ClinicalTrials.gov studies with "Pyridostigmine" as an intervention, any sponsor and status, largest first.

All 45 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • myasthenia gravis192
  • fatigue165
  • drug ineffective145
  • dyspnoea145
  • off label use130
  • asthenia121
  • headache115
  • diarrhoea113
  • nausea96
  • malaise90
  • dizziness76
  • fall72

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20049
200516
200618
200719
200845
200947
201037
201153
201245
201315
201424
201550
201685
201780
2018104
201978
2020128
2021128
2022109
2023177
2024240
2025241
2026158

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Pyridostigmine Bromide (Pyridostigmine Bromide)

2024 spending

$21.6M

Beneficiaries

62,621

258,983 claims

Per beneficiary

$345

$0.48 per unit

View as table
YearSpending
2020$21,368,327
2021$19,665,656
2022$21,871,760
2023$25,410,334
2024$21,587,647

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 233 on PubMed

Sponsor: Amneal

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.